A Phase 1, Multicenter, Open-label, Dose-escalation Study of Oral LGX818 in Adult Patients With Locally Advanced or Metastatic BRAF Mutant Melanoma
A Phase 1 Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Category & Conditions: Cancer
Medicine: BRAFTOVI® CAPSULES(ENCORAFENIB)
ClinicalTrials.gov Identifier (NCT): NCT01436656
Protocol ID: C4221010
PrintDownloadOpen Plain Language Summary Result: Click here